Aditx Therapeutics Inc
0.0 %
-97.15 %
Yet to be announced
Company Overview
Aditx Therapeutics, Inc. was a biotechnology company that focused on developing technologies to monitor, reprogram, and improve immune system function. The company's primary project was AditxtScore™, a technology platform for immune monitoring. However, the company ceased operations in 2023 and was delisted from Nasdaq.
Revenue Sources
Based on the financial data from the last four quarters, the company's revenues came from its core operations in immune monitoring technology development. There is no evidence of revenue from haram sources such as alcohol, gambling, or other prohibited activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $6,854 | $6.99m | - | $2.28m | 0.00% | 32.62% |
| June 30, 2024 | $44,276 | $7.67m | - | $1.65m | 0.00% | 21.49% |
| March 31, 2024 | $79,680 | $14.74m | - | $3.12m | 0.00% | 21.20% |
| Dec. 31, 2023 | $81,297 | $11.06m | - | $3.03m | 0.00% | 27.37% |
The company has significant interest expenses relative to its total expenses across all four quarters. Interest expenses consistently represent more than 20% of total expenses, which is well above acceptable thresholds. This indicates that interest-bearing debt plays a material role in the company's operations.
Operational Ethics
Based on available information, there is no evidence of significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.
Login to join the discussion